Skip to content

Clinical Outcomes

Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.

ThumbnailRichardWebinar1.3Plasma & Platelets

Transfusion transmitted bacterial infections in patients: why are they often undetected and underreported?


Dr. Richard J. Benjamin, MBChB, PhD, FRCPath
Cerus Corporation,
Concord, California, USA

EN DE PL ES RU 

ThumbnailCoppo

Plasma

Assessment of plasma preparations in TTP  

Prof. Dr. Paul Coppo, MD
CNR-MAT, AP-HP, Hóspital Saint-Antoine
Paris, France

EN DE 

ThumbnailOstermannPlatelets

Ordering platelet concentrates: does pathogen inactivation matter to the clinician?

Prof. Dr. Helmut Ostermann
LMU Kliniken, University of Munich
Munich, Germany

EN

ThumbnailPitmanPlatelets

Safety surveillance and the introduction of pathogen reduced platelets: the role of national hemovigilance systems in the Cerus post-market clinical follow-up strategy

Dr. John Pitman, PhD
Cerus Corporation
Concord, USA

EN

ThumbnailCid

Platelets

What does published literature tell us about the clinical efficacy of INTERCEPT treated platelets?

Dr. Joan Cid Vidal
Hospital Clínic
Barcelona, Spain

EN

ThumbnailOjedaPlatelets

Clinical performance of INTERCEPT and solvent detergent plasma used with idiopathic thrombotic purpura patients requiring therapeutic plasma exchanges

Dr. Mario Ojeda-Uribe, MD
Groupe Hospitalier Region Mulhouse Sud-Alsace (GHRMSA), Hospital E. Muller
Mulhouse, France

EN

ThumbnailLeitnerPlatelets

INTERCEPT treated platelets are effective in preventing bleeding

Ass. prof. Dr. Gerda Leitner
Medical University / General hospital Vienna
Vienna, Austria

EN

ThumbnailCognasse

Platelets & Plasma

Transfusing the right product to the right patient

Dr. Fabrice Cognasse, PhD
Auvergne-Rhône-Alpes Regional Blood Center of the French National Blood Establishment,
INSERM 1059 / University of Lyon
Saint-Etienne, France

EN  

  

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 000157, v43.0